Analyst · Madrigal Pharmaceuticals, Inc. (MDGL) | Ratings, Price Targets & Consensus

Analyst Consensus

Buy20 analysts

Buy

Updated Aug 6, 2026

Total Analysts20

Buy

20

Hold

2

Sell

1

Ratings

Updated Aug 6, 2026

Overall Rating

C

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$510.36

Median Target+31.06%

$668.90

Potential upside vs current price

DCF Value+444.63%

$2,779.57

Potential upside vs current price

Current Stock Price

$510.36

Median Target+31.06%

$668.90

Potential upside vs current price

DCF Value+444.63%

$2,779.57

Potential upside vs current price

Analyst Consensus

Buy20 analysts

Buy

Updated Aug 6, 2026

Total Analysts20

Buy

20

Hold

2

Sell

1

Ratings

Updated Aug 6, 2026

Overall Rating

C

DCF Score5.0 / 5

Debt / Equity Score1.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$510.36

Median Target+31.06%

$668.90

Potential upside vs current price

DCF Value+444.63%

$2,779.57

Potential upside vs current price

Current Stock Price

$510.36

Median Target+31.06%

$668.90

Potential upside vs current price

DCF Value+444.63%

$2,779.57

Potential upside vs current price